Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy
复制标题
DOI：
10.1097/00003072-200011000-00009
复制
发表时间：
2000-11-01
影响因子：
10.6
通讯作者：
Franke, WG
中科院分区：
文献类型：
--
作者：
Liepe, K;Kropp, J;Franke, WG
一名患有前列腺癌和多发性骨转移性疼痛的59岁男性接受1424 MBq （38.5 mCi）铼-186羟乙基二膦酸盐（Re-186 HEDP）治疗。此外，他有非甾体抗雄激素，孕激素和类似黄体生成素。未进行化疗或外束放疗。双膦酸盐治疗在给予Re-186 HEDP前4周停止。治疗后6周的Tc-99m HMDP全身扫描结果与治疗前相同。然而，治疗1年后，骨扫描显示转移瘤肿块明显减少。骨扫描指数由治疗前的34降至1年后的10。患者描述了明显的疼痛缓解，并在治疗3周后停止了止痛药的摄入。
A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38.5 mCi) rhenium-186 hydroxyethylidene diphosphonate (Re-186 HEDP). In addition, he had nonsteroidal antiandrogen, progestagen, and an analog-luteinizing hormone. Neither chemotherapy nor external-beam radiotherapy was administered. Bisphosponate therapy was stopped 4 weeks before the administration of Re-186 HEDP. The Tc-99m HMDP whole-body scan obtained 6 weeks after therapy showed the same results as before therapy. However, 1 year after therapy, a significant reduction of the mass of the metastases was visible on bone scan. The bone scan index decreased from 34 before therapy to 10 after 1 year. The patient described significant pain relief and stopped his analgesic intake 3 weeks after therapy.